论文部分内容阅读
目的：探讨卵巢癌抗独特型单链抗体６Ｂ１１ｓｃＦｖ／ｈＧＭＣＳＦ融合蛋白质（６Ｂ１１ＧＭ）作为肿瘤疫苗的可能性。方法：采用体外Ｔ细胞增殖试验，对６Ｂ１１ＧＭ刺激Ｔ细胞的能力进行测定，并用流式细胞仪对Ｔ细胞表型及ＡＰＣＭＨＣⅡ表达情况进行测定，测定了外周血单个核细胞经６Ｂ１１ＧＭ激活后对卵巢癌细胞系的非ＭＨＣ限制的杀伤活性。结果：６Ｂ１１ＧＭ及６Ｂ１１均能引起特异的Ｔ细胞增殖，但６Ｂ１１ＧＭ组的增殖明显高于６Ｂ１１组，以ＣＤ４＋增殖为主。６Ｂ１１ＧＭ能明显增加抗原提呈细胞（ａｎｔｉｇｅｎｐｒｅｓｅｎｔｉｎｇｃｅｌ，ＡＰＣ）的ＭＨＣⅡ表达，使ＡＰＣ更有效地摄取抗原，激活非ＭＨＣ限制的杀伤活性。结论：６Ｂ１１ＧＭ能引起细胞免疫反应，作为疫苗具有良好的前景
Objective: To investigate the possibility of ovarian cancer anti-idiotypic single chain antibody 6B11scFv / hGM-CSF fusion protein (6B11GM) as a tumor vaccine. Methods: T cell proliferation in vitro was used to test the ability of 6B11GM to stimulate T cells. The T cell phenotypes and the expression of APCMHC Ⅱ were determined by flow cytometry. The activation of peripheral blood mononuclear cells Non-MHC-restricted cytotoxic activity of cell lines. Results: 6B11GM and 6B11 all induced specific T cell proliferation. However, the proliferation of 6B11GM group was significantly higher than that of 6B11 group, mainly CD4 + proliferation. 6B11GM significantly increased MHC II expression of antigen presenting cells (APCs), allowing APCs to more efficiently uptake antigens and activate non-MHC-restricted cytotoxic activity. Conclusion: 6B11GM can induce cellular immune response and has good prospects as a vaccine